



Published in final edited form as:

*Mol Psychiatry*. 2019 November ; 24(11): 1668–1684. doi:10.1038/s41380-018-0061-1.

## NAD<sup>+</sup> cellular redox and SIRT1 regulate the diurnal rhythms of tyrosine hydroxylase and conditioned cocaine reward

Ryan W. Logan<sup>1,2,3</sup>, Puja K. Parekh<sup>1,2</sup>, Gabrielle Kaplan<sup>1,2</sup>, Darius Becker-Krail<sup>1,2</sup>, Wilbur Williams III<sup>1</sup>, Shintaro Yamaguchi<sup>3</sup>, Jun Yoshino<sup>3</sup>, Micah A. Shelton<sup>1</sup>, Xiyu Zhu<sup>1,2</sup>, Hui Zhang<sup>1,4</sup>, Spencer Waplinger<sup>1</sup>, Ethan Fitzgerald<sup>1</sup>, Jeffrey Oliver-Smith<sup>1</sup>, Poornima Sundarvelu<sup>1</sup>, John F. Enwright III<sup>1</sup>, Yanhua H. Huang, Colleen A. McClung<sup>1,2,3,\*</sup>

<sup>1</sup>Translational Neuroscience Program, Department of Psychiatry, University of Pittsburgh Medical School, Pittsburgh, PA, 15219, USA

<sup>2</sup>Center for Neuroscience, University of Pittsburgh, Pittsburgh, PA, 15260, USA

<sup>3</sup>Center for Systems Neurogenetics of Addiction, The Jackson Laboratory, Bar Harbor, ME, 04609

<sup>3</sup>Center for Human Nutrition, Division of Geriatrics and Nutritional Science, Department of Medicine, Washington University School of Medicine, St. Louis, MO, 63110, USA

<sup>4</sup>School of Medicine, Peking Union Medical College, Tsinghua University, Beijing, China

### Abstract

The diurnal regulation of dopamine is important for normal physiology and diseases such as addiction. Here we find a novel role for the CLOCK protein to antagonize CREB-mediated transcriptional activity at the tyrosine hydroxylase (*TH*) promoter, which is mediated by the interaction with the metabolic sensing protein, Sirtuin 1 (SIRT1). Additionally, we demonstrate that the transcriptional activity of *TH* is modulated by the cellular redox state, and daily rhythms of redox balance in the ventral tegmental area (VTA), along with *TH* transcription, is highly disrupted following chronic cocaine administration. Furthermore, CLOCK and SIRT1 are important for regulating cocaine reward and dopaminergic (DAergic) activity, with interesting differences depending on whether DAergic activity is in a heightened state and if there is a functional CLOCK protein. Taken together, we find that rhythms in cellular metabolism and circadian proteins work together to regulate dopamine synthesis and the reward value for drugs of abuse.

### INTRODUCTION

Many of the mechanisms underlying physiology and behavior are controlled by circadian rhythms. Studies from the liver find that organismal homeostasis is maintained by an interplay between circadian rhythms and metabolism<sup>1,2</sup>. Few studies have investigated these

Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use: [http://www.nature.com/authors/editorial\\_policies/license.html#terms](http://www.nature.com/authors/editorial_policies/license.html#terms)

\*Correspondence: [mcclungca@upmc.edu](mailto:mcclungca@upmc.edu) (C.A.M.).

CONFLICT OF INTEREST: The authors declare no conflicts of interest.

mechanisms in the mammalian brain, despite evidence linking circadian and/or metabolic disruptions to psychiatric disorders, including bipolar disorder and drug addiction<sup>3–7</sup>. Circadian disruption, whether environmental or genetic, alters the behavioral responses to drugs of abuse<sup>8–11</sup>. For example, circadian gene mutant mice display differential locomotor sensitization and conditioned preference to cocaine<sup>12,13</sup>, and self-administration of cocaine<sup>14</sup>, likely by modulating DA neurotransmission<sup>15–20</sup>.

At the cellular level, rhythms are controlled by transcriptional—translational feedback loops<sup>21</sup>, and ~40–50% of protein-coding genes are regulated by the molecular clock<sup>22</sup>. The core circadian transcription factors CLOCK and BMAL1 form heterodimers and bind to enhancer E-box promoter elements to directly control rhythmic gene transcription<sup>21</sup>. More recently, the molecular clock has been shown to couple with intracellular metabolic signaling pathways. One of the most well characterized is the interaction between CLOCK/BMAL1 and the energy-dependent histone and protein deacetylase SIRT1 to repress CLOCK-mediated transcription<sup>23–26</sup>. SIRT1 activity is modulated by the cofactor nicotinamide adenine dinucleotide (NAD<sup>+</sup>), and the reduced form, NADH, both of which respond to cellular energy demands and redox state<sup>27</sup>. Other studies have shown that NAD<sup>+</sup> is important for maintaining energy homeostasis in the brain<sup>28,29</sup>, as well as calcium transport and mitochondrial respiration<sup>29–33</sup>.

NAD<sup>+</sup> dependent SIRT1 regulates exploratory behavior, anxiety and depressive like behaviors, and reward and motivated behaviors associated with drugs of abuse<sup>34–38</sup>, suggesting a molecular link between circadian rhythms, metabolism, and psychiatric disorders. Moreover, drugs of abuse, including cocaine, alter cellular metabolism, redox state, and oxidative stress<sup>39–42</sup>. For example, fluctuations of NAD<sup>+</sup> modulate calcium influx to neural cells during DA stimulation, reducing NAD<sup>+</sup> bioavailability and attenuating further cellular activity<sup>43,44</sup>. A functional relationship between NAD<sup>+</sup> and DA in the brain may have implications in normal and pathological brain function.

Alterations in brain metabolism, circadian rhythms, and the mesolimbic DA system (ventral tegmental area (VTA) and nucleus accumbens (NAc)) contribute to the acute and prolonged effects on neural and behavioral plasticity of cocaine and other drugs of abuse<sup>45–50</sup>. Most neurons of the VTA are DAergic (~65%)<sup>51–53</sup>, which send projections to the amygdala, medial prefrontal cortex (mPFC), NAc and other striatal regions<sup>54–56</sup>. In the NAc, DA clearance follows a diurnal rhythm, which correlates with cocaine sensitization<sup>57,58</sup>. The VTA is central to reward and motivational behaviors<sup>59,60</sup>, and circadian disruption within the VTA is implicated in anxiety, depressive, and drug related behaviors<sup>18,61</sup>.

In the VTA, DAergic synthesis and release may be regulated by circadian rhythms. The rate-limiting step for DA synthesis is dependent on the availability and activity of tyrosine hydroxylase (TH)<sup>62–64</sup>. Interestingly, there are several putative circadian transcription factor binding motifs within the *TH* promoter<sup>15,65–67</sup>, including E-boxes<sup>68–71</sup>. The location of these E-boxes to the transcriptional start site (TSS) and the cAMP response element (CRE) site<sup>72,73</sup>, suggests direct transcriptional regulation of *TH* by CLOCK/BMAL1.

Our previous studies demonstrated that CLOCK disrupted, *Clock*<sup>-/-</sup> mice, are hyper-DAmergic<sup>18,74</sup>, with an elevated propensity to self-administer drugs of abuse<sup>14,75</sup>. The expression of *TH* in the VTA is also elevated in *Clock*<sup>-/-</sup> mice<sup>18,76</sup>, suggesting CLOCK may antagonize the transcriptional activity of *TH*, contrary to the typical transcriptional activation role of CLOCK. Here we demonstrate that the diurnal rhythm of *TH* is controlled by the diurnal dependent recruitment of CLOCK and CREB, whereby CLOCK and NAD<sup>+</sup> dependent regulation of SIRT1, antagonize CREB-induced transcription during the day, which is relieved during the night, allowing for CREB-mediated *TH* transcription. Moreover, these mechanisms are disrupted in *Clock*<sup>-/-</sup> mice leading to elevated CREB-mediated *TH* transcription during the day. We also report these transcription factors within the VTA are important for regulating conditioned place preference (CPP) for cocaine.

## MATERIALS AND METHODS

### Mice

Experiments used adult (9–16 weeks old) male wild-type (Wt) and *Clock*<sup>-/-</sup> mutant littermates on a BALB/c background grouped housed (2–4 per cage). For electrophysiological experiments, mice were between 5–6 weeks old at an age where abnormal behaviors of the *Clock*<sup>-/-</sup> mice are exhibited<sup>77</sup>. Mice were maintained on a 12:12 light-dark cycle (lights on at 700, ZT0, and lights off at 1900, ZT12) with food and water provided *ad libitum*. Separate cohorts of mice were used for each of the experiments described below with the exception of the following groups: Immunohistochemistry and gene expression was completed on subsets of mice following cocaine CPP. Animal use was conducted in accordance with the National Institute of Health guidelines and approved by the Institutional Animal Care and Use Committees of the University of Pittsburgh.

### Drug administration

Cocaine hydrochloride was provided by the National Institute on Drug Abuse and dissolved with saline (0.9%, Fisher Scientific). Mice were injected intraperitoneally (i.p.) with cocaine (5mg/kg for CPP), resveratrol (20mg/kg, SelleckChem, Houston, TX, USA), or saline (0.9%) at a volume of 10ml/kg. Systemic administration of resveratrol readily crosses the blood brain barrier<sup>78</sup>. For gene, protein, and NAD<sup>+</sup> expression studies (n=6 per group per ZT), cocaine (20mg/kg, i.p.) was administered acutely (single dose) or chronically (single dose per day for 14 days). Drugs were administered between ZT4–8.

### RNA isolation, cDNA, and qPCR

Mice were sacrificed throughout the LD cycle (n=6 per genotype per ZT) and brains were rapidly extracted and VTA was micropunched, followed by isolation of total RNA and cDNA synthesis to measure gene expression using qPCR, as described previously<sup>79</sup> (Supplementary Methods). Relative gene expression was calculated using the  $2^{-Ct}$  method, normalized to reference gene 18S, and reported as mean  $\pm$  SEM.

### SDS-PAGE Western blots

Mice were sacrificed throughout the LD cycle (n=6 per group or genotype per ZT) and brains were rapidly extracted and VTA was micropunched, followed by homogenization and

sonication. Protein lysate (10 $\mu$ g) were boiled then separated by SDS-PAGE and transferred to Immobilon-FL transfer membrane (Millipore), as described previously. The following primary antibodies were used:  $\beta$ -actin (1:2000; Sigma A2228), GAPDH (1:1000; Fitzgerald 10R-G109a), CREB (1:1000; Millipore MAB5432), phospho-CREB (1:1000; Millipore 06-519), and SIRT1 (1:1000; Millipore 07-131) (Supplementary Methods). Optical densities were quantified by NIH ImageJ software and normalized to the reference protein. Samples with values  $\pm 1.5$  standard deviations from group means were excluded.

### Chromatin immunoprecipitation (ChIP) assays

Midbrain punches were removed from fresh sections then pooled (n=6 pools (n=2 mice per pool) per genotype per ZT) and immediately cross-linked (1% paraformaldehyde), then incubated with glycine followed by homogenization and chromatin sheering (400–800bp fragments), as previously described<sup>18</sup>. Samples were incubated with antibodies for CLOCK, P-CREB, or SIRT1, coupled to magnetic beads. DNA associated protein was recovered using PCR Purification Kit (Qiagen). qPCR measured binding enrichment at the distal or proximal promoter of *TH*. Enrichment levels were calculated relative to the IgG control, as previously described<sup>18</sup>.

### TH:luc reporter in vitro assays

Rat pheochromocytoma (PC12) or mouse neuroblastoma (N2A) cells (ATCC, Manassas, VA, USA) were grown and maintained in high-glucose DMEM supplemented (Invitrogen) with 10% FBS (Invitrogen). SIRT1 KO MEFs and CLOCK KO MEFs were grown and maintained in DMEM supplemented with 5% FBS and 5% newborn calf serum (Sigma Aldrich). Semi-confluent cells (70–90%) were transfected with plasmids (5 $\mu$ g or 10 $\mu$ g) using Lipofectamine 2000 reagents (Invitrogen). Cells were lysed 48–72hrs post-transfection with 200 $\mu$ l of lysis buffer (Promega E1521, Fisher Scientific), then bioluminescence activity was measured. Luciferase activity was normalized to wells containing only *TH:luc* reporter plasmid and total protein. Plasmid construction of wild-type and E-box mutant *TH:luc* reporter gene constructs were prepared by inserting fragments (–1kb or –250bp) of the mouse promoter containing the putative TSS into a pGL3 luciferase vector. Mutagenic primers were designed to produce mutations at the putative E-box sites. CLOCK, CLOCK 19, and SIRT1 expression plasmids were cloned and modified. siRNA mediated transfection was used to knockdown SIRT1 (Santa Cruz Biotech, SC-108043). After transfection, PC12 cells and MEFs were also treated with bath application of NAD<sup>+</sup> ( $\beta$ -Nicotinamide adenine dinucleotide; Sigma, N8535), NMN ( $\beta$ -Nicotinamide mononucleotide; Sigma, N3501), NAM (Nicotinamide; Sigma, 73240), or the NAMPT-inhibitor, FK866 (SelleckChem, S2799).

### HPLC to measure NAD<sup>+</sup> levels from mouse brain tissue

Brain samples were rapidly extracted and flash frozen using liquid nitrogen (n=6 mice per ZT per genotype). Frozen tissue samples were rapidly homogenized in perchloric acid then neutralized in potassium carbonate. NAD<sup>+</sup> concentrations were determined using an HPLC system (Prominence; Shimadzu Scientific Instruments, Columbia, MD) with a Supelco LC-18-T column (Sigma, 58970-U), as described previously<sup>80,81</sup>. NAD<sup>+</sup> concentrations were normalized to weights of frozen tissue samples.

## Electrophysiology

Mice were anesthetized with isoflurane then decapitated to obtain horizontal brain sections (200 $\mu$ m) of the VTA (single cell sampled per slice; n=7 wild-type and n=6 *Clock* 19 mice). Whole cell current clamp recordings were conducted with a MultiClamp 700 amplified (Molecular Devices, Sunnyvale, CA, USA) on VTA neurons selected under differential interference contrast (DIC) optics. Dopamine cells were chosen based on their relatively larger size and characteristic electrophysiological properties, including the HCN channel-mediated ‘sag’ current at hyperpolarizing current steps and spontaneous firing of 1–3Hz (Supplementary Information). Following stable baseline recordings, resveratrol (SIRT1 activator; 50 $\mu$ M dissolved in 0.1% DMSO) was bath applied for ~20min. One cell was sampled per slice. pClamp 10 software (Molecular Devices) was used for recordings and subsequent analyses. Spikes were counted manually and rheobase was measured as the minimum current required to elicit action potentials.

## HPLC to measure catecholamine and metabolites

Mouse brains were sectioned and microdissected for PFC, NAc, dSTR, and VTA, then frozen on dry ice (n=6 per genotype per ZT). Microdissected punches were homogenized. Supernatant was removed for biogenic monoamines analyses using HPLC. Using the HPLC solvent, the following biogenic amines elute in the following order: DOPAC, dopamine, and HVA. HPLC control and data acquisition are managed by Empower software. HPLC assays were conducted by the Neurochemistry Core at the Vanderbilt Brain Institute.

## Stereotaxic surgery

Mice underwent stereotaxic brain surgery to bilaterally inject into the VTA (relative to bregma: angle 7°; AP, -3.2; ML,  $\pm$ 1.0; DV, -4.6), high titer viruses (1 $\mu$ l) encoding either AAV5 GFP-Scrambled or GFP-mutant CREB (mCREB), or bicistronic (GFP driven by cytomegalovirus promoter and SIRT1 driven by IE4/5 promoter) p1005 herpes simplex virus (HSV) vectors with GFP alone or GFP with SIRT1 (SIRT-OX)<sup>34</sup> (Supplementary Methods). Mice injected with AAV5 constructs recovered for 3–4 weeks, while mice injected with HSV constructs recovered for 2–3 days prior to behavioral testing to allow for maximal viral expression.

## Immunohistochemistry

Mice were deeply anesthetized then perfused (4% paraformaldehyde). Sections (30 $\mu$ M) were processed for GFP, TH, and DAPI, then secondary fluorophore antibodies (Supplementary Methods). Sections were imaged with an epifluorescent microscope (4 $\times$ , 10 $\times$  and 40 $\times$ ). Mice were excluded if viral spread was not localized to the VTA, with viral spread through the injection tract, or with asymmetrical infection between hemispheres (~5% of mice).

## Conditioned place preference (CPP)

Mice underwent cocaine place conditioning as described previously<sup>13</sup>. A biased conditioning protocol was used since most mice (>75%) preferred one chamber or the other during the pre-test (Day 1). On days 2–5, mice were either injected with saline or cocaine (5mg/kg, i.p.) then placed into the white or black chamber for 20 min. On day 6, mice were

given no injections and allowed to freely explore the apparatus and the amount of time spent each of the three chambers was measured. Stereotaxic virally injected mice recovered prior to cocaine CPP (n=10–11 per group). Mice were injected on days 2–5 exactly 30 min prior to saline or cocaine with resveratrol (20mg/kg, i.p., dissolved in 5% hydroxypropyl  $\beta$ -cyclodextrin, Sigma Aldrich, n=9 per group). Mice were injected between ZT9–11 on days 1–5 (~12–16 hrs prior to CPP) with saline or the NAD<sup>+</sup> precursor, NMN ( $\beta$ -Nicotinamide mononucleotide, 500mg/kg, i.p., dissolved in saline, Sigma Aldrich, n=9–10 per group). The CPP score was calculated as the amount of time spent within the conditioned chamber on the test day subtracted from the amount of time spent on the same side on the pretest day.

## Statistics

Sample sizes for each of the experiments were based on previous studies and/or power calculations from unpublished pilot experiments. Animals were assigned randomly to treatment groups to balance age, cage, and littermates across genotypes where applicable. Diurnal variation of gene, protein, and NAD<sup>+</sup> expression was analyzed using CircWave v1.4 software (courtesy of Dr. Roelof Hut, [www.euclock.org](http://www.euclock.org)). Sin-cosine regression was constrained to a period of 24hrs, single harmonic, with significance at  $\alpha=0.05$ . The center of gravity for each fitted waveform was used to estimate acrophase, or peak, of diurnal variation. Unpaired Student's t-test was used to test significance between genotypes where noted. One-way ANOVA followed by Tukey's multiple comparisons tests were used to test differences between groups for *in vitro* experiments where noted. Two-way ANOVA were used to examine main effects of genotype, treatment, condition, or time, and interactions for *in vitro* and *in vivo* experiments. Significant interactions (genotype  $\times$  treatment or genotype  $\times$  time) were followed by *post-hoc* tests (Tukey's, Dunnett's, or Sidak's, where appropriate). Data are expressed as mean  $\pm$  SEM with a two-tailed  $\alpha=0.05$  considered statistically significant. Data were processed using Microsoft Excel, CircWave, ImageJ, and GraphPad Prism software.

## RESULTS

### The molecular clock regulates TH expression and DA levels in mouse midbrain and striatum

Mice with the *Clock*<sup>19</sup> mutation display disrupted DA rhythms<sup>18,76,82</sup>, and elevated levels of TH<sup>76</sup>, suggesting a link between CLOCK and DA synthesis. The <sup>19</sup> mutation renders a dominant negative protein unable to promote gene transcription<sup>83,84</sup>. *TH* is diurnally expressed with a peak (acrophase) during the night (or active) phase of light-dark (LD) cycle (Figure 1A), which is increased during the day and early night with a shift in acrophase in *Clock*<sup>19</sup> mice with a disrupted molecular clock (Figure 1A and Figure S1C–F,I). Protein expression of TH and the phosphorylated form (P-THser40) are increased during the day and night (Figure S1A,B), suggesting activated TH may be constitutively elevated in *Clock*<sup>19</sup>.

The mouse *TH* promoter contains two canonical E-Boxes (CACGTG)—~1341bp and ~233bp upstream from the TSS referred to as distal and proximal, respectively (Figure 1B). The proximal E-box is located near the CRE site (~79bp to TSS), where CREB binds to



activate transcription<sup>85,86</sup>. The proximity of these sites to the TSS, and to one another, suggest diurnal dependent regulation by CLOCK and CREB. Chromatin immunoprecipitation (ChIP) assays reveals antiphasic P-CREB and CLOCK binding at the proximal E-box of *TH* promoter, whereby P-CREB and CLOCK preferentially bind during the night and day, respectively (Figure 1C and Figure 1D). CLOCK peaks at ZT4 (also at distal E-box, Figure S2C) when *TH* troughs, and P-CREB peaks at ZT16 when *TH* peaks (no binding of either P-CREB or SIRT1 at the distal promoter, Figure S2A,B; CLOCK IP verified using *Clock* knock out mice, Figure S2D). SIRT1 also binds with a diurnal pattern at the proximal promoter, peaking during the day (Figure 1E).

In *Clock*<sup>-/-</sup> mice, diurnal binding at the proximal promoter of P-CREB, CLOCK and SIRT1 is lost (Figure 1C–E). SIRT1 occupancy is almost undetectable (Figure 1E), potentially due to reduced SIRT1 at ZT4 (Figure 1H). There are no diurnal differences in CREB (Figure 1F), although P-CREB expression appears to increase at ZT4 and decrease at ZT16 (Figure 1G), while SIRT1 shows the opposite pattern of expression in *Clock*<sup>-/-</sup> mice (Figure 1H), suggesting disrupted diurnal variation of expression. Diurnal variation of *Sirt1* gene (Figure S1H) and SIRT1 protein (Figure 1H) are lost in *Clock*<sup>-/-</sup> mice, and the rhythm of the CLOCK target gene *Nampt* is completely reversed (Figure S1G,I), further indicative of disrupted SIRT1 signaling. Given the elevated *TH* levels during the day in *Clock*<sup>-/-</sup> mice and the diurnal patterns of promoter binding of these transcription factors, CLOCK may repress the transcriptional activity of *TH* at specific times of day when SIRT1 is also present.

As expected, levels of DA and the metabolites 3–4-Dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA) of the VTA and areas downstream, the dSTR and mPFC are altered in *Clock*<sup>-/-</sup> mice (Figure 1I–L). DA levels are elevated in the dSTR (Figure 1I), VTA (Figure 1K), and NAc (Figure 1L), but reduced in the mPFC (Figure 1J), with higher DOPAC/DA and HVA/DA ratios in the VTA and lower ratios in the dSTR in *Clock*<sup>-/-</sup> mice. These findings indicate a dominant negative CLOCK protein consequently impacts *TH* transcription, and levels of DA and metabolites, in mesocorticolimbic pathways, including the dSTR, mPFC, NAc, and VTA.

### **CLOCK represses CREB-induced TH transcription by interacting with SIRT1**

We designed *TH* promoter constructs expressing either the distal and/or proximal regions containing the E-Box and CRE sites driving a luciferase reporter (*TH:luc*). Cells were transfected with any of the following mouse expression constructs: CREB, CLOCK, CLOCK<sup>-/-</sup>, and/or SIRT1, and *TH:luc*. As expected, CREB reliably induces *TH:luc* activity (Figure 2A, PC12 and Figure 2F, MEFs). In PC12 cells, CREB-induced *TH:luc* activity is completely blocked by CLOCK, but not CLOCK<sup>-/-</sup> (Figure 2A). Mutation of the proximal E-box (CACGTG to CCCGGG) where CLOCK preferentially binds during the day, prevents CLOCK-mediated antagonism of CREB-induced activity (Figure 2B). Similar effects are observed following mutation of the distal E-box (Figure S3A).

Based on our findings (see Figure 1) and those from liver and other tissues<sup>24,25</sup>, we investigated whether CLOCK represses transcriptional activity via the recruitment of SIRT1 (Figure S4). CLOCK transfected with SIRT1 further reduces *TH:luc* activity, whereas

siRNA-mediated knockdown of *Sirt1* prevents the effects of CLOCK on CREB-induced transcriptional activity (Figure 2C). SIRT1 restored the repressive effects of CLOCK 19 (Figure 2D). We then used Wt, CLOCK KO, and SIRT1 KO MEFs to investigate whether CLOCK and/or SIRT1 are necessary for reducing transcriptional activity. CLOCK fails to reduce activity in SIRT1 KO MEFs, yet when CLOCK and SIRT1 are co-transfected, activity is reduced (Figure 2E). The interaction between CLOCK and SIRT1 requires the N-terminus region of SIRT1 (aa1-231)<sup>24</sup>. In CLOCK KO MEFs, constructs expressing the catalytic domain or the C-terminus of SIRT1 has no effect on *TH:luc* activity, while the N-terminus region is sufficient for recapitulating SIRT1-mediated repression (Figure 2F).

### Cellular metabolic cofactors of SIRT1 modulate TH gene transcriptional activity

NAD<sup>+</sup> and intermediate enzymes of the NAD<sup>+</sup> salvage pathway controls the activity of SIRT1 (Figure S4)<sup>24,26,87,88</sup>. NAD<sup>+</sup> (1μM) blocks CREB-induced *TH:luc* activity (Figure 2G), consistent with the role of SIRT1 from our findings. Indeed, SIRT1 knockdown attenuates the effects of NAD<sup>+</sup> on *TH:luc* activity (Figure 2J). NAM is a byproduct of NAD<sup>+</sup> metabolism and part of the biosynthesis pathway regulating SIRT1<sup>89</sup>. As expected, CLOCK antagonism of CREB-induced *TH:luc* activity is prevented by NAM (Figure 2H and Figure S3A). The precursor NMN is necessary for NAD<sup>+</sup> biosynthesis and NAD<sup>+</sup> dependent SIRT1 activity (Figure S4)<sup>90,91</sup>. Similar to NAD<sup>+</sup>, NMN prevents CREB-induced *TH:luc* activity and further attenuates activity with CLOCK or SIRT1 (Figure 2K). SIRT1KO MEFs treated with NMN (400 or 800μM) and transfected with CLOCK produces minimal changes on CREB-induced *TH:luc* activity unless SIRT1 is also present (Figure 2L). NAD<sup>+</sup> synthesis is controlled by the rate-limiting enzyme NAMPT. The NAMPT inhibitor FK866 (10nM), which recapitulates the effects of SIRT1 inhibition via NAD<sup>+</sup> depletion<sup>24,25,92</sup>, attenuates the repressive effects of CLOCK, CLOCK/SIRT1, and CLOCK 19/SIRT1 on CREB-induced transcription (Figure S3C). These findings collectively demonstrate NAD<sup>+</sup> bioavailability and biosynthesis contributes to the ability of CLOCK/SIRT1 to reduce the transcriptional potential of *TH*, thus linking CLOCK activity to the redox state. To further demonstrate these mechanisms are important for endogenous *TH* regulation in neural cells, we transfected mouse N2A cells. Similar to our findings in PC12 and MEF cells, CLOCK alone has no effect on basal *TH:luc* activity (Figure 3A), while CLOCK or SIRT1 prevents CREB-induced activity, with CLOCK 19 having no effect (Figure 3B).

Mice treated with resveratrol (20mg/kg, daily i.p., 4 days), a pharmacological activator of SIRT1<sup>93</sup>, display reduced *TH* expression in the VTA (Figure 3D). *In vivo* manipulation of SIRT1 (HSV-SIRT1) specifically within the VTA of Wt and *Clock* 19 mice (Figure 3C) also reduces *TH* expression (Figure 3E), whereas the effects of mCREB in VTA are genotype dependent (Figure 3F). Thus, SIRT1 represses *TH* expression *in vivo*, while CREB may differentially regulate transcription depending on a functional CLOCK protein, and these results suggest overactive CREB activity in *Clock* 19 mice (Supplementary table 2).



### The effects of SIRT1 activation on VTA DA physiology and striatal DA levels depends on a functional CLOCK protein

We performed whole-cell current-clamp recordings from VTA DA cells (Figure S5). Using cell-attached recordings, slices were treated with vehicle (DMSO) followed by resveratrol. Resveratrol increases and decreases spike frequency in Wt and *Clock*<sup>-/-</sup> mice, respectively (Figure 4A,C,D). VTA DA neurons are more depolarized in *Clock*<sup>-/-</sup> mice, indicating enhanced excitability (Figure 4B), consistent with our previous findings reporting increased spontaneous firing of DA neurons in slice and *in vivo*<sup>76,82</sup>, which is reduced by resveratrol (Figure 4E,F). Consistent with our physiology findings, resveratrol increases DA levels in the NAc and dSTR of Wt mice, and reduces DA and DOPAC only in the NAc of *Clock*<sup>-/-</sup> mice (Figure 4G,H and Figure S6), with no effects in the mPFC (Figure S7). Resveratrol modulates DA cell firing depending on a functional molecular clock and basal DAergic tone from the VTA—i.e., resveratrol enhances DA signaling in Wt mice with low to normal tone and reduces DA in *Clock*<sup>-/-</sup> mice with high tone (Figure 4I).

### Diurnal variations of NAD<sup>+</sup> and SIRT1 in VTA are affected by cocaine

To further extend these findings to the brain, we measured diurnal rhythms of NAD<sup>+</sup> in the VTA using HPLC since NAD<sup>+</sup> rhythms regulate SIRT1 in liver and other tissues. Intriguingly, NAD<sup>+</sup> peaks during the middle of the day (Figure S8A), when: SIRT1 binds the *TH* promoter (Figure 1E); SIRT1 expression peaks (Figure S8B); and *TH* troughs (Figure 1A and Figure S8E). Cocaine is known to alter redox state, SIRT1 activity, and the cellular response to DA<sup>34,35,38,44,46,94–97</sup>. Thus, we investigated the effects of cocaine on diurnal rhythms of NAD<sup>+</sup> and SIRT1 in the VTA. Acute cocaine (20mg/kg, i.p., single injection) has no impact on NAD<sup>+</sup>, however, there is a complete loss of diurnal rhythm following chronic cocaine (20mg/kg, i.p., 14 days) (Figure S8C and Figure S9A). SIRT1 diurnal rhythms are also lost following cocaine (Figure S8D), along with disruption in other circadian and metabolic genes (Figure S9) with minimal effects on CREB or P-CREB (Figure S9H,I). Acute cocaine completely flattens the diurnal rhythm of *TH*, which remains substantially dampened following chronic cocaine (Figure S8E). Diurnal rhythms of NAD<sup>+</sup> and SIRT1 overlap, with peaks at the same times of day, and in antiphase to *TH* expression, which are altered by cocaine (Figure S8F).

### The effects of SIRT1 activation on cocaine CPP depends on a functional CLOCK protein

Mice injected with AAV5-mCREB or HSV-SIRT1 into the VTA, or treated with resveratrol or NMN were subjected to cocaine CPP to determine whether these mechanisms are important for drug conditioned reward (Figure 5A). The effects of mCREB or SIRT1 activation led to opposite expression of *TH* in Wt and *Clock*<sup>-/-</sup> mice following cocaine CPP (Figure 5B, Resveratrol; Figure 5C, NMN; Figure 5D, SIRT1OX; and Figure 5E, mCREB). Consistent with our previous findings<sup>76</sup>, elevated cocaine CPP is robust in *Clock*<sup>-/-</sup> mice (Figure 5F–I). Resveratrol (Figure 5F), NMN (Figure 5G), SIRT1 (Figure 5H), or mCREB (Figure 5I), almost completely prevents cocaine CPP in *Clock*<sup>-/-</sup> mice, yet enhances CPP in Wt mice, further supporting the differential regulation of VTA DAergic activity by NAD-dependent SIRT1 when DAergic cells are in a heightened or normal state. Taken together, our results demonstrate that CLOCK, SIRT1 and CREB are capable of

bidirectionally modulating the *in vivo* transcriptional activity of *TH* and cocaine conditioned reward (Supplementary table 2).

## DISCUSSION

Disruptions to the circadian system are linked to addiction and other psychiatric disorders. Metabolic oscillations are tightly coupled with the molecular clock<sup>2,25,98</sup>. Our results showing time of day dependent expression of *TH*, transcriptional activity, and promoter occupancy of CLOCK, SIRT1, and CREB, together with our previous reports<sup>14,18,74,76,77,82</sup>, suggest circadian-dependent regulation of pathways involved in DA synthesis. Diurnal variation of *TH* transcription is regulated by time of day dependent recruitment of CLOCK and SIRT1 to the proximal promoter in antiphase to CREB. During the day (inactive), CLOCK and SIRT1 reduce the transcriptional activity of *TH*, while CREB promotes transcription during the night (active). Furthermore, pharmacological activation of SIRT1 can modulate the excitability and firing of VTA DA neurons and DA levels downstream of the VTA. These mechanisms are disrupted by cocaine administration and this is important for the regulation of cocaine conditioned reward. Together, our data support previous findings in peripheral tissues indicating coupling of metabolic and molecular clock pathways, which are important in the regulation of a number of physiological processes.

We establish here a functional role for NAD<sup>+</sup> dependent regulation of SIRT1 signaling on CLOCK-mediated transcription of *TH*. NAM inhibits SIRT1 activity through the metabolizing of NAD<sup>+</sup><sup>99-102</sup>. Transcriptional activity of *TH* is attenuated by NAD<sup>+</sup> and restored with NAM presumably by modulating SIRT1 activity, since these effects are less robust following SIRT1 knockdown or SIRT1KO MEFs. The immediate precursor to NAD<sup>+</sup>, NMN, also reduces CREB-induced transcriptional activity, further supporting the role of NAD<sup>+</sup> biosynthesis as a key regulator of SIRT1-mediated transcriptional repression.

The conversion of NAM to  $\beta$ -NMN is catalyzed by the CLOCK target gene, NAMPT, positioning this enzyme as a pivotal factor coupling metabolic and circadian oscillators. The expression of *Nampt* and *Sirt1* peak near similar diurnal phases and antiphasic to SIRT1 and NAD<sup>+</sup> levels, suggesting NAD<sup>+</sup> dependent SIRT1 activity represses *TH* expression during the inactive phase. Daily rhythms of NAD<sup>+</sup> directly modulates the diurnal activity of CLOCK/BMAL1/SIRT1 transcriptional complexes<sup>24,99</sup>. Consistent with this, CLOCK and SIRT1 preferentially bind the *TH* promoter during the day when NAD<sup>+</sup> peaks and *TH* expression is low. Moreover, the repression of transcriptional activity is dependent on the presence of the N-terminus of SIRT1, which has previously been shown to be necessary for the interaction with CLOCK<sup>87</sup>. Together, these findings strongly suggest CLOCK-mediated repression of *TH* expression is dependent on NAD<sup>+</sup> and the interaction with SIRT1.

Our findings suggest a functional CLOCK is able to antagonize CREB-mediated transcriptional activity of *TH*, where CLOCK promoter occupancy during the day, when *TH* expression is the lowest, prevents CREB occupancy. We previously reported significantly increased *TH* expression and altered DA synthesis in the VTA of *Clock*<sup>-/-</sup> 19 mice<sup>18,76</sup>. We extend these findings to demonstrate these changes in *TH* expression are likely due to impaired SIRT1 function or activity. While CLOCK<sup>-/-</sup> 19 protein is still capable of binding

the promoter, SIRT1 binding (and expression) is markedly lower, potentially allowing for CREB recruitment and transcriptional activation. Another possibility is steric hindrance where the CLOCK protein at the E-box site prevents CREB binding at certain times of day. Due to a splicing misread and the excision of exon 19, the mutant CLOCK protein is missing 51 amino acids of the transactivational domain<sup>84</sup>. In *Clock*<sup>19</sup> mice, CREB-induced transcriptional activity remains and P-CREB binding at the CRE site is constitutively enriched during day and night. Thus, the truncated CLOCK protein may permit CREB to bind and regulate *TH* transcription. Other genes are directly regulated by CLOCK/BMAL1 complexes and CREB, suggesting potential common mechanisms of circadian dependent transcription at other gene promoters<sup>103,104</sup>. Pleiotropic or 'non-circadian' roles of these transcription factors may also be involved. The repression of transcriptional activity by CLOCK could be independent of circadian regulation, especially when considering the impact of cocaine on these mechanisms. For example, SIRT1 suppresses the transcriptional activity of *TH* under non-stimulated conditions, while over-expression or activation seems to increase *TH* expression if animals are also exposed to cocaine. Cocaine likely disrupts the typical action of these transcription factors or the activation of other cofactors and pathways. Interestingly, SIRT1 can both activate or inhibit transcription depending on the recruitment of additional cofactors or post-translational modifiers, and brain region<sup>34,87,105</sup>.

The synthesis and release of DA is modulated by several pathways of the circadian system. For example, the dopamine transporter (DAT) has been shown to be necessary for diurnal variation of extracellular dopamine tone<sup>16</sup>. Moreover, midbrain *TH* expression seems to be also controlled by REV-ERB $\alpha$  and NURR1 to repress or promote transcription, respectively<sup>15</sup>. Interestingly, *Rev-erba* and *Clock*<sup>19</sup> mutant mice are both hyper-DAergic and exhibit reduced anxiety-like and depressive-like behaviors<sup>15,18</sup>. Our previous studies suggest altered DA synthesis and release in *Clock*<sup>19</sup> mice may be specific to the VTA and largely unaffected in the substantia nigra, suggesting complementary yet regionally distinct regulation of *TH* by molecular clock mechanisms, however this has not been systematically investigated<sup>15,18</sup>. CLOCK, in addition to other transcription factors, regulates the expression of *Rev-erba*. Despite changes in liver of *Clock*<sup>19</sup> mice<sup>106</sup>, we found diurnal expression of *Rev-erba* was minimally affected, and may indicate these observed changes in *TH* of *Clock*<sup>19</sup> mice are independent of REV-ERB $\alpha$ .

The complete loss of CLOCK (e.g., CLOCK KO mice) may be compensated by NPAS2<sup>107–110</sup>. NPAS2 and CLOCK independently dimerize with BMAL1 to maintain rhythms in various tissues<sup>107,111</sup>. However, *Clock*<sup>19</sup> mice gradually become arrhythmic in constant conditions<sup>112–114</sup>, suggesting NPAS2 fails to compensate. Moreover, the CLOCK<sup>19</sup> protein is capable of binding BMAL1, yet fails to recruit cofactors required for transcription<sup>84</sup>, and leads to blunted molecular rhythms<sup>115</sup>, consistent with our findings of flattened *Per2* rhythms. In contrast, the diurnal variation of another CLOCK target gene *Nampt* was completely reversed in *Clock*<sup>19</sup> mice and *TH* expression appeared to phase-shifted with an overall increase in amplitude. Altered phase resetting, reduced circadian amplitudes, and phase shifts in *Clock*<sup>19</sup> mice has also been observed for other molecular and behavioral rhythms<sup>116,117</sup>. Nevertheless, our results show *Clock*<sup>19</sup> mice have constitutively elevated activated TH in the VTA, further suggesting genetic disruption of the

molecular clock disrupts DAergic transmission<sup>18</sup>. In addition, NPAS2 has little to no expression in the VTA<sup>118</sup>, suggesting compensation by NPAS2 is unlikely to play a role in these studies.

Highly metabolic tissues, such as liver and brain, may rely on the coupling between metabolic and circadian oscillators in order to maintain homeostasis, energy utilization, and overall tissue health. An important cofactor with responsiveness to changes in cellular metabolism, mitochondrial biogenesis, and redox state is NAD<sup>+</sup>. NAD<sup>+</sup> is almost completely depleted following DA stimulation, which is thought to be a consequence of the cells attempting to meet the energy demands of the mitochondria<sup>43,44</sup>. Interestingly, chronic, but not acute, cocaine completely flattened the diurnal variations of NAD<sup>+</sup> in the VTA, suggesting repeated administration of cocaine taxes mitochondrial function and impairs NAD<sup>+</sup> signaling<sup>119</sup>. Chronic administration of drugs of abuse could impair neuronal metabolism, interfere with subsequent responses to stimuli, and promote oxidative stress.

The loss of rhythms of firing and release of DA from VTA neurons parallels loss of rhythms of locomotor activity, cocaine CPP and self-administration in *Clock*<sup>-19</sup> mice<sup>14,18,74–76</sup>. We replicate these findings of increased sensitivity to cocaine conditioned reward in these mice, which may be due to elevated extracellular DA and DA turnover in the VTA and downstream striatal regions. As suggested, overactive CREB-mediated transcription of *TH* may be responsible for an overall increase of TH gene and protein expression in the VTA of *Clock*<sup>-19</sup> mice. Indeed, VTA-specific viral over-expression of mutant CREB significantly reduces *TH* expression selectively in these mice, which is similar to over-expression of SIRT1, and pharmacological activation of SIRT1 by resveratrol. The reduction in *TH* expression corresponds with attenuated cocaine conditioned reward. In addition, bath application of resveratrol to VTA slices from *Clock*<sup>-19</sup> mice reduces the excitability and firing of DA neurons, further supporting the idea that SIRT1 activation antagonizes DA driven hyperhedonia in *Clock*<sup>-19</sup> mice. Other studies have shown that preventing SIRT1 in the NAc relieves stress-induced depressive-like behaviors<sup>36</sup> and attenuates drug self-administration<sup>34,35,38</sup>. Thus targeting of SIRT1 or NAD<sup>+</sup> dependent pathways may have therapeutic implications for those with comorbid mood, substance use, and metabolic disorders<sup>120–123</sup>.

Repeated cocaine administration increases the expression of SIRT1 in the NAc, and SIRT1 activation either by over-expression or resveratrol activation can promote cocaine CPP and self-administration<sup>34,35,38</sup>. Similarly, systemically administered resveratrol, NMN, or VTA-specific over-expression of SIRT1 in wild-type mice increases cocaine CPP, potentially via enhanced DA neuronal excitability and extracellular DA in the NAc and dSTR. Expression of *TH* in the VTA is also increased following SIRT1 activation and cocaine administration in wild-type mice. These findings seem contrary to our initial results demonstrating SIRT1 activation reduces the transcriptional activity of *TH* *in vitro* and *in vivo*. We speculate that suppressed *TH* expression following mCREB or SIRT1-OX may lead to compensatory changes of DA neuronal activity or potentiated neural responses to cocaine. Cocaine may further perturb these molecular mechanisms which could underlie these discrepancies since cocaine altered the diurnal expression of TH, SIRT1, and NAD<sup>+</sup>. On the other hand, we observed the opposite direction of effects in *Clock*<sup>-19</sup> mice, suggesting that when DA

neuronal firing is constitutively elevated, mCREB or SIRT1 activation reduces DA activity and cocaine CPP. Future studies will need to further tease apart the mechanisms underlying these differences. Nevertheless, our findings collectively point towards NAD<sup>+</sup> dependent SIRT1-mediated modulation of DA signaling involving CLOCK in the VTA.

Taken together, our results demonstrate diurnal variation of *TH* in the VTA is regulated by NAD<sup>+</sup> dependent SIRT1 activity and CLOCK-mediated repression. These mechanisms may have important applications for substance use and implications for other psychiatric disorders. Targeting NAD<sup>+</sup> or SIRT1 may be effective therapeutic approaches for comorbid mood and substance use disorders.

## Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

## Acknowledgments

We would like to thank Mark Brown and Mariah Hildebrand for animal care and genotyping. We also thank Eric Nestler, Deveroux Ferguson and Rachel Neve for the mCREB and SIRT1 viruses, and Gary Thomas for the SIRT1 partial constructs. We thank Joe Takahashi for the *Clock*<sup>-19</sup> mice and CLOCK expression constructs. This work was funded by: DA039865, DA037636, MH106460, MH082876, DA023988, DA042886, NS058339, NARSAD and IMHRO to Dr. McClung, and DA038564, DA041872, and NARSAD to Dr. Logan.

## References

1. Cribbet MR, Logan RW, Edwards MD, Hanlon E, Bien Peek C, Stubblefield JJ, et al. Circadian rhythms and metabolism: from the brain to the gut and back again. *Ann N Y Acad Sci.* 2016; 1385(1):21–40. [PubMed: 27589593]
2. Eckel-Mahan K, Sassone-Corsi P. Metabolism and the circadian clock converge. *Physiol Rev.* 2013; 93(1):107–135. [PubMed: 23303907]
3. Vengeliene V, Cannella N, Takahashi T, Spanagel R. Metabolic shift of the kynurenine pathway impairs alcohol and cocaine seeking and relapse. *Psychopharmacology (Berl).* 2016; 233(18):3449–3459. [PubMed: 27475106]
4. Barandas R, Landgraf D, McCarthy MJ, Welsh DK. Circadian Clocks as Modulators of Metabolic Comorbidity in Psychiatric Disorders. *Curr Psychiatry Rep.* 2015; 17(12):98. [PubMed: 26483181]
5. Kaidanovich-Beilin O, Cha DS, McIntyre RS. Crosstalk between metabolic and neuropsychiatric disorders. *F1000 Biol Rep.* 2012; 4:14. [PubMed: 22802875]
6. Karatsoreos IN. Links between Circadian Rhythms and Psychiatric Disease. *Front Behav Neurosci.* 2014; 8:162. [PubMed: 24834040]
7. Takahashi JS, Hong HK, Ko CH, McDearmon EL. The genetics of mammalian circadian order and disorder: implications for physiology and disease. *Nat Rev Genet.* 2008; 9(10):764–775. [PubMed: 18802415]
8. Abarca C, Albrecht U, Spanagel R. Cocaine sensitization and reward are under the influence of circadian genes and rhythm. *Proc Natl Acad Sci U S A.* 2002; 99(13):9026–9030. [PubMed: 12084940]
9. Andretic R, Chaney S, Hirsh J. Requirement of circadian genes for cocaine sensitization in *Drosophila*. *Science.* 1999; 285(5430):1066–1068. [PubMed: 10446052]
10. Jansen HT, Sergeeva A, Stark G, Sorg BA. Circadian discrimination of reward: evidence for simultaneous yet separable food- and drug-entrained rhythms in the rat. *Chronobiol Int.* 2012; 29(4):454–468. [PubMed: 22475541]
11. Sleipness EP, Sorg BA, Jansen HT. Diurnal differences in dopamine transporter and tyrosine hydroxylase levels in rat brain: dependence on the suprachiasmatic nucleus. *Brain Res.* 2007; 1129(1):34–42. [PubMed: 17156761]

12. Halbout B, Perreau-Lenz S, Dixon CI, Stephens DN, Spanagel R. Per1(Brdm1) mice self-administer cocaine and reinstate cocaine-seeking behaviour following extinction. *Behav Pharmacol.* 2011; 22(1):76–80. [PubMed: 21127416]
13. Ozburn AR, Falcon E, Twaddle A, Nugent AL, Gillman AG, Spencer SM, et al. Direct regulation of diurnal Drd3 expression and cocaine reward by NPAS2. *Biol Psychiatry.* 2015; 77(5):425–433. [PubMed: 25444159]
14. Ozburn AR, Larson EB, Self DW, McClung CA. Cocaine self-administration behaviors in ClockDelta19 mice. *Psychopharmacology (Berl).* 2012; 223(2):169–177. [PubMed: 22535308]
15. Chung S, Lee EJ, Yun S, Choe HK, Park SB, Son HJ, et al. Impact of circadian nuclear receptor REV-ERBalpha on midbrain dopamine production and mood regulation. *Cell.* 2014; 157(4):858–868. [PubMed: 24813609]
16. Ferris MJ, Espana RA, Locke JL, Konstantopoulos JK, Rose JH, Chen R, et al. Dopamine transporters govern diurnal variation in extracellular dopamine tone. *Proc Natl Acad Sci U S A.* 2014; 111(26):E2751–2759. [PubMed: 24979798]
17. Shumay E, Fowler JS, Wang GJ, Logan J, Alia-Klein N, Goldstein RZ, et al. Repeat variation in the human PER2 gene as a new genetic marker associated with cocaine addiction and brain dopamine D2 receptor availability. *Transl Psychiatry.* 2012; 2:e86. [PubMed: 22832851]
18. Sidor MM, Spencer SM, Dzirasa K, Parekh PK, Tye KM, Warden MR, et al. Daytime spikes in dopaminergic activity drive rapid mood-cycling in mice. *Mol Psychiatry.* 2015; 20(11):1406–1419. [PubMed: 25560763]
19. Sorg BA, Chen SY, Kalivas PW. Time course of tyrosine hydroxylase expression after behavioral sensitization to cocaine. *J Pharmacol Exp Ther.* 1993; 266(1):424–430. [PubMed: 8101222]
20. Spanagel R, Pendyala G, Abarca C, Zghoul T, Sanchis-Segura C, Magnone MC, et al. The clock gene Per2 influences the glutamatergic system and modulates alcohol consumption. *Nat Med.* 2005; 11(1):35–42. [PubMed: 15608650]
21. Takahashi JS. Transcriptional architecture of the mammalian circadian clock. *Nat Rev Genet.* 2017; 18(3):164–179. [PubMed: 27990019]
22. Zhang R, Lahens NF, Ballance HI, Hughes ME, Hogenesch JB. A circadian gene expression atlas in mammals: implications for biology and medicine. *Proc Natl Acad Sci U S A.* 2014; 111(45):16219–16224. [PubMed: 25349387]
23. Asher G, Gatfield D, Stratmann M, Reinke H, Dibner C, Kreppel F, et al. SIRT1 regulates circadian clock gene expression through PER2 deacetylation. *Cell.* 2008; 134(2):317–328. [PubMed: 18662546]
24. Nakahata Y, Kaluzova M, Grimaldi B, Sahar S, Hirayama J, Chen D, et al. The NAD<sup>+</sup>-dependent deacetylase SIRT1 modulates CLOCK-mediated chromatin remodeling and circadian control. *Cell.* 2008; 134(2):329–340. [PubMed: 18662547]
25. Nakahata Y, Sahar S, Astarita G, Kaluzova M, Sassone-Corsi P. Circadian control of the NAD<sup>+</sup> salvage pathway by CLOCK-SIRT1. *Science.* 2009; 324(5927):654–657. [PubMed: 19286518]
26. Ramsey KM, Yoshino J, Brace CS, Abrassart D, Kobayashi Y, Marcheva B, et al. Circadian clock feedback cycle through NAMPT-mediated NAD<sup>+</sup> biosynthesis. *Science.* 2009; 324(5927):651–654. [PubMed: 19299583]
27. Houtkooper RH, Canto C, Wanders RJ, Auwerx J. The secret life of NAD<sup>+</sup>: an old metabolite controlling new metabolic signaling pathways. *Endocr Rev.* 2010; 31(2):194–223. [PubMed: 20007326]
28. Hirrlinger J, Dringen R. The cytosolic redox state of astrocytes: Maintenance, regulation and functional implications for metabolite trafficking. *Brain Res Rev.* 2010; 63(1–2):177–188. [PubMed: 19883686]
29. Ying W. NAD<sup>+</sup> and NADH in brain functions, brain diseases and brain aging. *Front Biosci.* 2007; 12:1863–1888. [PubMed: 17127427]
30. Henley J, Poo MM. Guiding neuronal growth cones using Ca<sup>2+</sup> signals. *Trends Cell Biol.* 2004; 14(6):320–330. [PubMed: 15183189]
31. Konur S, Ghosh A. Calcium signaling and the control of dendritic development. *Neuron.* 2005; 46(3):401–405. [PubMed: 15882639]



32. Liang M, Yin XL, Wang LY, Yin WH, Song NY, Shi HB, et al. NAD<sup>+</sup> Attenuates Bilirubin-Induced Hyperexcitation in the Ventral Cochlear Nucleus by Inhibiting Excitatory Neurotransmission and Neuronal Excitability. *Front Cell Neurosci.* 2017; 11:21. [PubMed: 28217084]
33. Tamsett TJ, Picchione KE, Bhattacharjee A. NAD<sup>+</sup> activates KNa channels in dorsal root ganglion neurons. *J Neurosci.* 2009; 29(16):5127–5134. [PubMed: 19386908]
34. Ferguson D, Koo JW, Feng J, Heller E, Rabkin J, Heshmati M, et al. Essential role of SIRT1 signaling in the nucleus accumbens in cocaine and morphine action. *J Neurosci.* 2013; 33(41):16088–16098. [PubMed: 24107942]
35. Ferguson D, Shao N, Heller E, Feng J, Neve R, Kim HD, et al. SIRT1-FOXO3a regulate cocaine actions in the nucleus accumbens. *J Neurosci.* 2015; 35(7):3100–3111. [PubMed: 25698746]
36. Kim HD, Hesterman J, Call T, Magazu S, Keeley E, Armenta K, et al. SIRT1 Mediates Depression-Like Behaviors in the Nucleus Accumbens. *J Neurosci.* 2016; 36(32):8441–8452. [PubMed: 27511015]
37. Libert S, Pointer K, Bell EL, Das A, Cohen DE, Asara JM, et al. SIRT1 activates MAO-A in the brain to mediate anxiety and exploratory drive. *Cell.* 2011; 147(7):1459–1472. [PubMed: 22169038]
38. Renthall W, Kumar A, Xiao G, Wilkinson M, Covington HE 3rd, Maze I, et al. Genome-wide analysis of chromatin regulation by cocaine reveals a role for sirtuins. *Neuron.* 2009; 62(3):335–348. [PubMed: 19447090]
39. Aksenov MY, Aksenova MV, Nath A, Ray PD, Mactutus CF, Booze RM. Cocaine-mediated enhancement of Tat toxicity in rat hippocampal cell cultures: the role of oxidative stress and D1 dopamine receptor. *Neurotoxicology.* 2006; 27(2):217–228. [PubMed: 16386305]
40. Lopez-Pedrajas R, Ramirez-Lamelas DT, Muriach B, Sanchez-Villarejo MV, Almansa I, Vidal-Gil L, et al. Cocaine promotes oxidative stress and microglial-macrophage activation in rat cerebellum. *Front Cell Neurosci.* 2015; 9:279. [PubMed: 26283916]
41. Muriach M, Lopez-Pedrajas R, Barcia JM, Sanchez-Villarejo MV, Almansa I, Romero FJ. Cocaine causes memory and learning impairments in rats: involvement of nuclear factor kappa B and oxidative stress, and prevention by topiramate. *J Neurochem.* 2010; 114(3):675–684. [PubMed: 20477932]
42. Pomierny-Chamiolo L, Moniczewski A, Wydra K, Suder A, Filip M. Oxidative stress biomarkers in some rat brain structures and peripheral organs underwent cocaine. *Neurotox Res.* 2013; 23(1):92–102. [PubMed: 22791409]
43. Requardt RP, Wilhelm F, Rillich J, Winkler U, Hirrlinger J. The biphasic NAD(P)H fluorescence response of astrocytes to dopamine reflects the metabolic actions of oxidative phosphorylation and glycolysis. *J Neurochem.* 2010; 115(2):483–492. [PubMed: 20698931]
44. Requardt RP, Hirrlinger PG, Wilhelm F, Winkler U, Besser S, Hirrlinger J. Ca<sup>2+</sup>(+) signals of astrocytes are modulated by the NAD(+)/NADH redox state. *J Neurochem.* 2012; 120(6):1014–1025. [PubMed: 22299833]
45. Sordi AO, Pechansky F, Kessler FH, Kapczinski F, Pfaffenseller B, Gubert C, et al. Oxidative stress and BDNF as possible markers for the severity of crack cocaine use in early withdrawal. *Psychopharmacology (Berl).* 2014; 231(20):4031–4039. [PubMed: 24676990]
46. Uys JD, Knackstedt L, Hurt P, Tew KD, Manevich Y, Hutchens S, et al. Cocaine-induced adaptations in cellular redox balance contributes to enduring behavioral plasticity. *Neuropsychopharmacology.* 2011; 36(12):2551–2560. [PubMed: 21796101]
47. Berke JD, Hyman SE. Addiction, dopamine, and the molecular mechanisms of memory. *Neuron.* 2000; 25(3):515–532. [PubMed: 10774721]
48. Nutt DJ, Lingford-Hughes A, Erritzoe D, Stokes PR. The dopamine theory of addiction: 40 years of highs and lows. *Nat Rev Neurosci.* 2015; 16(5):305–312. [PubMed: 25873042]
49. Volkow ND. Imaging the addicted brain: from molecules to behavior. *J Nucl Med.* 2004; 45(11)
50. Volkow ND, Morales M. The Brain on Drugs: From Reward to Addiction. *Cell.* 2015; 162(4):712–725. [PubMed: 26276628]


51. Margolis EB, Lock H, Hjelmstad GO, Fields HL. The ventral tegmental area revisited: is there an electrophysiological marker for dopaminergic neurons? *J Physiol*. 2006; 577(Pt 3):907–924. [PubMed: 16959856]
52. Nair-Roberts RG, Chatelain-Badie SD, Benson E, White-Cooper H, Bolam JP, Ungless MA. Stereological estimates of dopaminergic, GABAergic and glutamatergic neurons in the ventral tegmental area, substantia nigra and retrorubral field in the rat. *Neuroscience*. 2008; 152(4):1024–1031. [PubMed: 18355970]
53. Swanson LW. The projections of the ventral tegmental area and adjacent regions: a combined fluorescent retrograde tracer and immunofluorescence study in the rat. *Brain Res Bull*. 1982; 9(1–6):321–353. [PubMed: 6816390]
54. Kabanova A, Pabst M, Lorkowski M, Braganza O, Boehlen A, Nikbakht N, et al. Function and developmental origin of a mesocortical inhibitory circuit. *Nat Neurosci*. 2015; 18(6):872–882. [PubMed: 25961790]
55. Morales M, Margolis EB. Ventral tegmental area: cellular heterogeneity, connectivity and behaviour. *Nat Rev Neurosci*. 2017; 18(2):73–85. [PubMed: 28053327]
56. Zhang JT, Ma SS, Yip SW, Wang LJ, Chen C, Yan CG, et al. Decreased functional connectivity between ventral tegmental area and nucleus accumbens in Internet gaming disorder: evidence from resting state functional magnetic resonance imaging. *Behav Brain Funct*. 2015; 11(1):37. [PubMed: 26582309]
57. Sleipness EP, Jansen HT, Schenk JO, Sorg BA. Time-of-day differences in dopamine clearance in the rat medial prefrontal cortex and nucleus accumbens. *Synapse*. 2008; 62(12):877–885. [PubMed: 18792987]
58. Sleipness EP, Sorg BA, Jansen HT. Time of day alters long-term sensitization to cocaine in rats. *Brain Res*. 2005; 1065(1–2):132–137. [PubMed: 16309631]
59. Luscher C, Malenka RC. Drug-evoked synaptic plasticity in addiction: from molecular changes to circuit remodeling. *Neuron*. 2011; 69(4):650–663. [PubMed: 21338877]
60. Nestler EJ, Carlezon WA Jr. The mesolimbic dopamine reward circuit in depression. *Biol Psychiatry*. 2006; 59(12):1151–1159. [PubMed: 16566899]
61. Logan RW, McClung CA. Animal models of bipolar mania: The past, present and future. *Neuroscience*. 2016; 321:163–188. [PubMed: 26314632]
62. Biguet NF, Buda M, Lamouroux A, Samolyk D, Mallet J. Time course of the changes of TH mRNA in rat brain and adrenal medulla after a single injection of reserpine. *EMBO J*. 1986; 5(2):287–291. [PubMed: 2872048]
63. Fossom LH, Carlson CD, Tank AW. Stimulation of tyrosine hydroxylase gene transcription rate by nicotine in rat adrenal medulla. *Mol Pharmacol*. 1991; 40(2):193–202. [PubMed: 1678851]
64. Tank AW, Lewis EJ, Chikaraishi DM, Weiner N. Elevation of RNA coding for tyrosine hydroxylase in rat adrenal gland by reserpine treatment and exposure to cold. *J Neurochem*. 1985; 45(4):1030–1033. [PubMed: 2863328]
65. Cambi F, Fung B, Chikaraishi D. 5' flanking DNA sequences direct cell-specific expression of rat tyrosine hydroxylase. *J Neurochem*. 1989; 53(5):1656–1659. [PubMed: 2571679]
66. Iwata N, Kobayashi K, Sasaoka T, Hidaka H, Nagatsu T. Structure of the mouse tyrosine hydroxylase gene. *Biochem Biophys Res Commun*. 1992; 182(1):348–354. [PubMed: 1346248]
67. Kobayashi K, Kaneda N, Ichinose H, Kishi F, Nakazawa A, Kurosawa Y, et al. Structure of the human tyrosine hydroxylase gene: alternative splicing from a single gene accounts for generation of four mRNA types. *J Biochem*. 1988; 103(6):907–912. [PubMed: 2902075]
68. Gekakis N, Staknis D, Nguyen HB, Davis FC, Wilsbacher LD, King DP, et al. Role of the CLOCK protein in the mammalian circadian mechanism. *Science*. 1998; 280(5369):1564–1569. [PubMed: 9616112]
69. Kumaki Y, Ukai-Tadenuma M, Uno KD, Nishio J, Masumoto KH, Nagano M, et al. Analysis and synthesis of high-amplitude Cis-elements in the mammalian circadian clock. *Proc Natl Acad Sci U S A*. 2008; 105(39):14946–14951. [PubMed: 18815372]
70. Yoo SH, Ko CH, Lowrey PL, Buhr ED, Song EJ, Chang S, et al. A noncanonical E-box enhancer drives mouse Period2 circadian oscillations in vivo. *Proc Natl Acad Sci U S A*. 2005; 102(7):2608–2613. [PubMed: 15699353]

71. Yoshitane H, Ozaki H, Terajima H, Du NH, Suzuki Y, Fujimori T, et al. CLOCK-controlled polyphonic regulation of circadian rhythms through canonical and noncanonical E-boxes. *Mol Cell Biol.* 2014; 34(10):1776–1787. [PubMed: 24591654]
72. Lazaroff M, Patankar S, Yoon SO, Chikaraishi DM. The cyclic AMP response element directs tyrosine hydroxylase expression in catecholaminergic central and peripheral nervous system cell lines from transgenic mice. *J Biol Chem.* 1995; 270(37):21579–21589. [PubMed: 7665571]
73. Olson VG, Zabetian CP, Bolanos CA, Edwards S, Barrot M, Eisch AJ, et al. Regulation of drug reward by cAMP response element-binding protein: evidence for two functionally distinct subregions of the ventral tegmental area. *J Neurosci.* 2005; 25(23):5553–5562. [PubMed: 15944383]
74. Roybal K, Theobald D, Graham A, DiNieri JA, Russo SJ, Krishnan V, et al. Mania-like behavior induced by disruption of CLOCK. *Proc Natl Acad Sci U S A.* 2007; 104(15):6406–6411. [PubMed: 17379666]
75. Ozburn AR, Falcon E, Mukherjee S, Gillman A, Arey R, Spencer S, et al. The role of clock in ethanol-related behaviors. *Neuropsychopharmacology.* 2013; 38(12):2393–2400. [PubMed: 23722243]
76. McClung CA, Sidiropoulou K, Vitaterna M, Takahashi JS, White FJ, Cooper DC, et al. Regulation of dopaminergic transmission and cocaine reward by the Clock gene. *Proc Natl Acad Sci U S A.* 2005; 102(26):9377–9381. [PubMed: 15967985]
77. Parekh PK, Becker-Krail D, Sundaravelu P, Ishigaki S, Okado H, Sobue G, et al. Altered GluA1 (Gria1) Function and Accumbal Synaptic Plasticity in the ClockDelta19 Model of Bipolar Mania. *Biol Psychiatry.* 2017
78. Baur JA, Sinclair DA. Therapeutic potential of resveratrol: the in vivo evidence. *Nat Rev Drug Discov.* 2006; 5(6):493–506. [PubMed: 16732220]
79. Spencer S, Falcon E, Kumar J, Krishnan V, Mukherjee S, Birnbaum SG, et al. Circadian genes Period 1 and Period 2 in the nucleus accumbens regulate anxiety-related behavior. *Eur J Neurosci.* 2013; 37(2):242–250. [PubMed: 23039899]
80. Stromsdorfer KL, Yamaguchi S, Yoon MJ, Moseley AC, Franczyk MP, Kelly SC, et al. NAMPT-Mediated NAD(+) Biosynthesis in Adipocytes Regulates Adipose Tissue Function and Multi-organ Insulin Sensitivity in Mice. *Cell Rep.* 2016; 16(7):1851–1860. [PubMed: 27498863]
81. Yoshino J, Imai S. Accurate measurement of nicotinamide adenine dinucleotide (NAD(+)) with high-performance liquid chromatography. *Methods Mol Biol.* 2013; 1077:203–215. [PubMed: 24014409]
82. Coque L, Mukherjee S, Cao JL, Spencer S, Marvin M, Falcon E, et al. Specific role of VTA dopamine neuronal firing rates and morphology in the reversal of anxiety-related, but not depression-related behavior in the ClockDelta19 mouse model of mania. *Neuropsychopharmacology.* 2011; 36(7):1478–1488. [PubMed: 21430648]
83. King DP, Vitaterna MH, Chang AM, Dove WF, Pinto LH, Turek FW, et al. The mouse Clock mutation behaves as an antimorph and maps within the W19H deletion, distal of Kit. *Genetics.* 1997; 146(3):1049–1060. [PubMed: 9215907]
84. King DP, Zhao Y, Sangoram AM, Wilsbacher LD, Tanaka M, Antoch MP, et al. Positional cloning of the mouse circadian clock gene. *Cell.* 1997; 89(4):641–653. [PubMed: 9160755]
85. Lewis-Tuffin LJ, Quinn PG, Chikaraishi DM. Tyrosine hydroxylase transcription depends primarily on cAMP response element activity, regardless of the type of inducing stimulus. *Mol Cell Neurosci.* 2004; 25(3):536–547. [PubMed: 15033181]
86. Piech-Dumas KM, Tank AW. CREB mediates the cAMP-responsiveness of the tyrosine hydroxylase gene: use of an antisense RNA strategy to produce CREB-deficient PC12 cell lines. *Brain Res Mol Brain Res.* 1999; 70(2):219–230. [PubMed: 10407170]
87. Aguilar-Arnal L, Katada S, Orozco-Solis R, Sassone-Corsi P. NAD(+)-SIRT1 control of H3K4 trimethylation through circadian deacetylation of MLL1. *Nat Struct Mol Biol.* 2015; 22(4):312–318. [PubMed: 25751424]
88. Canto C, Gerhart-Hines Z, Feige JN, Lagouge M, Noriega L, Milne JC, et al. AMPK regulates energy expenditure by modulating NAD+ metabolism and SIRT1 activity. *Nature.* 2009; 458(7241):1056–1060. [PubMed: 19262508]

89. Bitterman KJ, Anderson RM, Cohen HY, Latorre-Esteves M, Sinclair DA. Inhibition of silencing and accelerated aging by nicotinamide, a putative negative regulator of yeast sir2 and human SIRT1. *J Biol Chem.* 2002; 277(47):45099–45107. [PubMed: 12297502]
90. Berger F, Lau C, Dahlmann M, Ziegler M. Subcellular compartmentation and differential catalytic properties of the three human nicotinamide mononucleotide adenylyltransferase isoforms. *J Biol Chem.* 2005; 280(43):36334–36341. [PubMed: 16118205]
91. Koch-Nolte F, Fischer S, Haag F, Ziegler M. Compartmentation of NAD<sup>+</sup>-dependent signalling. *FEBS Lett.* 2011; 585(11):1651–1656. [PubMed: 21443875]
92. Hasmann M, Schemainda I. FK866, a highly specific noncompetitive inhibitor of nicotinamide phosphoribosyltransferase, represents a novel mechanism for induction of tumor cell apoptosis. *Cancer Res.* 2003; 63(21):7436–7442. [PubMed: 14612543]
93. Hu Y, Liu J, Wang J, Liu Q. The controversial links among calorie restriction, SIRT1, and resveratrol. *Free Radic Biol Med.* 2011; 51(2):250–256. [PubMed: 21569839]
94. Dietrich JB, Mangeol A, Revel MO, Burgun C, Aunis D, Zwiller J. Acute or repeated cocaine administration generates reactive oxygen species and induces antioxidant enzyme activity in dopaminergic rat brain structures. *Neuropharmacology.* 2005; 48(7):965–974. [PubMed: 15857623]
95. Gimenez-Xavier P, Gomez-Santos C, Castano E, Francisco R, Boada J, Unzeta M, et al. The decrease of NAD(P)H has a prominent role in dopamine toxicity. *Biochim Biophys Acta.* 2006; 1762(5):564–574. [PubMed: 16574383]
96. Macedo DS, de Vasconcelos SM, dos Santos RS, Aguiar LM, Lima VT, Viana GS, et al. Cocaine alters catalase activity in prefrontal cortex and striatum of mice. *Neurosci Lett.* 2005; 387(1):53–56. [PubMed: 16085363]
97. Numa R, Kohen R, Poltyrev T, Yaka R. Tempol diminishes cocaine-induced oxidative damage and attenuates the development and expression of behavioral sensitization. *Neuroscience.* 2008; 155(3):649–658. [PubMed: 18619523]
98. Bellet MM, Orozco-Solis R, Sahar S, Eckel-Mahan K, Sassone-Corsi P. The time of metabolism: NAD<sup>+</sup>, SIRT1, and the circadian clock. *Cold Spring Harb Symp Quant Biol.* 2011; 76:31–38. [PubMed: 22179986]
99. Aguilar-Arnal L, Ranjit S, Stringari C, Orozco-Solis R, Gratton E, Sassone-Corsi P. Spatial dynamics of SIRT1 and the subnuclear distribution of NADH species. *Proc Natl Acad Sci U S A.* 2016
100. Fulco M, Schiltz RL, Iezzi S, King MT, Zhao P, Kashiwaya Y, et al. Sir2 regulates skeletal muscle differentiation as a potential sensor of the redox state. *Mol Cell.* 2003; 12(1):51–62. [PubMed: 12887892]
101. Prozorovski T, Schulze-Topphoff U, Glumm R, Baumgart J, Schroter F, Ninnemann O, et al. Sirt1 contributes critically to the redox-dependent fate of neural progenitors. *Nat Cell Biol.* 2008; 10(4):385–394. [PubMed: 18344989]
102. Revollo JR, Grimm AA, Imai S. The NAD biosynthesis pathway mediated by nicotinamide phosphoribosyltransferase regulates Sir2 activity in mammalian cells. *J Biol Chem.* 2004; 279(49):50754–50763. [PubMed: 15381699]
103. Obrietan K, Impey S, Smith D, Athos J, Storm DR. Circadian regulation of cAMP response element-mediated gene expression in the suprachiasmatic nuclei. *J Biol Chem.* 1999; 274(25):17748–17756. [PubMed: 10364217]
104. Travnickova-Bendova Z, Cermakian N, Reppert SM, Sassone-Corsi P. Bimodal regulation of mPeriod promoters by CREB-dependent signaling and CLOCK/BMAL1 activity. *Proc Natl Acad Sci U S A.* 2002; 99(11):7728–7733. [PubMed: 12032351]
105. Chang HC, Guarente L. SIRT1 mediates central circadian control in the SCN by a mechanism that decays with aging. *Cell.* 2013; 153(7):1448–1460. [PubMed: 23791176]
106. Hughes ME, Hong HK, Chong JL, Indacochea AA, Lee SS, Han M, et al. Brain-specific rescue of Clock reveals system-driven transcriptional rhythms in peripheral tissue. *PLoS Genet.* 2012; 8(7):e1002835. [PubMed: 22844252]
107. DeBruyne JP, Weaver DR, Reppert SM. CLOCK and NPAS2 have overlapping roles in the suprachiasmatic circadian clock. *Nat Neurosci.* 2007; 10(5):543–545. [PubMed: 17417633]

108. Gu YZ, Hogenesch JB, Bradfield CA. The PAS superfamily: sensors of environmental and developmental signals. *Annu Rev Pharmacol Toxicol.* 2000; 40:519–561. [PubMed: 10836146]
109. Hogenesch JB, Chan WK, Jackiw VH, Brown RC, Gu YZ, Pray-Grant M, et al. Characterization of a subset of the basic-helix-loop-helix-PAS superfamily that interacts with components of the dioxin signaling pathway. *J Biol Chem.* 1997; 272(13):8581–8593. [PubMed: 9079689]
110. Reick M, Garcia JA, Dudley C, McKnight SL. NPAS2: an analog of clock operative in the mammalian forebrain. *Science.* 2001; 293(5529):506–509. [PubMed: 11441147]
111. Landgraf D, Wang LL, Diemer T, Welsh DK. NPAS2 Compensates for Loss of CLOCK in Peripheral Circadian Oscillators. *PLoS Genet.* 2016; 12(2):e1005882. [PubMed: 26895328]
112. Kennaway DJ, Voultzios A, Varcoe TJ, Moyer RW. Melatonin and activity rhythm responses to light pulses in mice with the Clock mutation. *Am J Physiol Regul Integr Comp Physiol.* 2003; 284(5):R1231–1240. [PubMed: 12521925]
113. Ochi M, Sono S, Sei H, Oishi K, Kobayashi H, Morita Y, et al. Sex difference in circadian period of body temperature in Clock mutant mice with Jcl/ICR background. *Neurosci Lett.* 2003; 347(3):163–166. [PubMed: 12875911]
114. Vitaterna MH, King DP, Chang AM, Kornhauser JM, Lowrey PL, McDonald JD, et al. Mutagenesis and mapping of a mouse gene, Clock, essential for circadian behavior. *Science.* 1994; 264(5159):719–725. [PubMed: 8171325]
115. Ripperger JA, Schibler U. Rhythmic CLOCK-BMAL1 binding to multiple E-box motifs drives circadian Dbp transcription and chromatin transitions. *Nat Genet.* 2006; 38(3):369–374. [PubMed: 16474407]
116. Vitaterna MH, Ko CH, Chang AM, Buhr ED, Fruechte EM, Schook A, et al. The mouse Clock mutation reduces circadian pacemaker amplitude and enhances efficacy of resetting stimuli and phase-response curve amplitude. *Proc Natl Acad Sci U S A.* 2006; 103(24):9327–9332. [PubMed: 16754844]
117. Redlin U, Hattar S, Mrosovsky N. The circadian Clock mutant mouse: impaired masking response to light. *J Comp Physiol A Neuroethol Sens Neural Behav Physiol.* 2005; 191(1):51–59. [PubMed: 15558289]
118. Garcia JA, Zhang D, Estill SJ, Michnoff C, Rutter J, Reick M, et al. Impaired cued and contextual memory in NPAS2-deficient mice. *Science.* 2000; 288(5474):2226–2230. [PubMed: 10864874]
119. Zhang Y, Xue Y, Meng S, Luo Y, Liang J, Li J, et al. Inhibition of Lactate Transport Erases Drug Memory and Prevents Drug Relapse. *Biol Psychiatry.* 2016; 79(11):928–939. [PubMed: 26293178]
120. Abe N, Uchida S, Otsuki K, Hobara T, Yamagata H, Higuchi F, et al. Altered sirtuin deacetylase gene expression in patients with a mood disorder. *J Psychiatr Res.* 2011; 45(8):1106–1112. [PubMed: 21349544]
121. Kishi T, Fukuo Y, Kitajima T, Okochi T, Yamanouchi Y, Kinoshita Y, et al. SIRT1 gene, schizophrenia and bipolar disorder in the Japanese population: an association study. *Genes Brain Behav.* 2011; 10(3):257–263. [PubMed: 20977650]
122. Kishi T, Yoshimura R, Fukuo Y, Kitajima T, Okochi T, Matsunaga S, et al. The CLOCK gene and mood disorders: a case-control study and meta-analysis. *Chronobiol Int.* 2011; 28(9):825–833. [PubMed: 22080789]
123. Nivoli A, Porcelli S, Albani D, Forloni G, Fusco F, Colom F, et al. Association between Sirtuin 1 Gene rs10997870 Polymorphism and Suicide Behaviors in Bipolar Disorder. *Neuropsychobiology.* 2016; 74(1):1–7. [PubMed: 27424200]





**Figure 1. CLOCK Regulates the Diurnal Expression of *TH* in the VTA**

(A) *TH* expression is significantly elevated during the day in the VTA of *Clock* $\Delta$ 19 mice (ZT  $\times$  genotype,  $F_{5,60}=3.95$ ,  $p<0.01$ ; Sidak's post hoc tests, \*\*  $p<0.01$ ). Peak expression is shifted earlier during the active phase ( $t=6.4$ ,  $p<0.0001$ ). Sine wave fit ( $p<0.05$ ) with multi-harmonic regression assuming 24hr period are superimposed on mean  $\pm$  SEM (Wt, black; *Clock* $\Delta$ 19, blue).  $n=6$  mice per ZT per genotype.

(B) Mouse *TH* promoter with canonical binding sites for CLOCK (E-boxes; white) and CREB (CRE; black) proximal to the ATG start site (arrowhead) and core promoter (gray box).

(C–E) Diurnal variation of P-CREB, CLOCK, and SIRT1 binding to the proximal promoter site. (C) P-CREB binding peaks during the night in Wt mice and remains constitutively elevated in *Clock* $\Delta$ 19 mice (ZT,  $F_{1,16}=6.5$ , #  $p=0.02$  and genotype,  $F_{1,16}=13.12$ ,  $p=0.002$ ).

(D) CLOCK binding peaks during the day in Wt mice (antiphase to P-CREB), with significantly reduced binding in *Clock* $\Delta$ 19 mice (ZT  $\times$  genotype,  $F_{1,16}=32.84$ ,  $p<0.0001$ ; Tukey's post hoc tests, \*\*\*\*  $p<0.0001$ , a Wt ZT4 vs. ZT16,  $p<0.0001$ ).

(E) SIRT1 binding peaks during the day, similarly to CLOCK in Wt mice with no detectable binding in *Clock* $\Delta$ 19 mice (ZT  $\times$  genotype,  $F_{1,16}=8.75$ ,  $p<0.01$ ; Tukey's post hoc tests, \*\*  $p<0.01$ , a Wt




ZT4 vs. ZT16,  $p=0.01$ ). Red dotted line marks IgG background level.  $n=6$  mice per ZT per genotype.

(F) CREB expression is unchanged in the VTA of *Clock*<sup>-/-</sup> mice.

(G) P-CREB expression is reduced in the VTA of *Clock*<sup>-/-</sup> mice (ZT  $\times$  genotype,  $F_{1,12}=10.54$ ,  $p<0.01$ ; Tukey's post hoc tests, a *Clock*<sup>-/-</sup> ZT4 vs. ZT16,  $p=0.02$ ).

(H) SIRT1 expression varies across day and night in Wt mice with reduced expression during the day in *Clock*<sup>-/-</sup> mice (ZT  $\times$  genotype,  $F_{1,12}=16.65$ ,  $p<0.01$ ; Tukey's post-hoc, \*  $p<0.05$ , a *Clock*<sup>-/-</sup> ZT4 vs. ZT16,  $p<0.01$ ).

(I–L) Brain regions were collected at ZT8–10 when *TH* expression is nearing the peak in *Clock*<sup>-/-</sup> mice then levels of DA and metabolites were measured using HPLC. Levels of DA ( $t=13.33$ , \*\*\*\*  $p<0.0001$ ), DOPAC ( $t=4.6$ , \*\*\*  $p<0.001$ ), and HVA ( $t=5.96$ , \*\*\*  $p<0.001$ ), are increased, with unchanged DOPAC/DA ratio and reduced HVA/DA ratios ( $t=6.25$ , \*\*\*\*  $p<0.0001$ ) in the dSTR of *Clock*<sup>-/-</sup> mice (I). In addition, DA levels are reduced in the mPFC of *Clock*<sup>-/-</sup> mice ( $t=2.52$ , \*  $p<0.05$ ), and DOPAC ( $t=6.98$ , \*\*\*\*  $p<0.0001$ ), HVA ( $t=5.1$ , \*\*\*  $P<0.001$ ), and DOPAC/DA ( $t=6.13$ , \*\*\*  $p<0.001$ ) and HVA/DA ( $t=3.58$ , \*\*  $p<0.01$ ) ratios are also increased (J). Levels of DA ( $t=5.01$ ), DOPAC ( $t=3.13$ ) and HVA ( $t=2.65$ ) are increased in the VTA, with reduced DOPAC/DA ( $t=2.23$ ) and HVA/DA ( $t=2.39$ ) ratios (K). DA ( $t=4.1$ ), DOPAC ( $t=3.31$ ) and HVA ( $t=3.4$ ) are in the NAc of *Clock*<sup>-/-</sup> mice, with no changes in ratios (L). \*  $p<0.05$ , \*\*  $p<0.01$ , \*\*\*  $p<0.001$ . All data are represented as mean  $\pm$  SEM.  $n=6$  mice per ZT per genotype.



**Figure 2. CLOCK, SIRT1, and Metabolic Cofactors Modulate the Transcriptional Activity of TH** (A) PC12 cells were transfected and *TH:Luc* promoter activity was measured. CREB induces activity of *TH:Luc*, which is prevented by co-transfection with CLOCK, while CLOCK 19 fails to do so (one-way ANOVA,  $F_{4,30}=35.1$ ,  $p<0.0001$ ; Tukey's post hoc tests, \*\*\*\*  $p<0.0001$ ). Amount of CLOCK plasmid transfected (small circle, 1 $\mu$ g; large circle, 10 $\mu$ g).  $n=8-15$  per condition, data represents an average across triplicate wells and multiple plates. (B) Mutation of the proximal E-box site of the *TH* promoter prevents the ability of CLOCK to repress transcriptional activity (one-way ANOVA,  $F_{7,24}=250.3$ ,  $p<0.0001$ ; Tukey's post

hoc tests, a TH vs. TH/CREB/CLOCK  $p < 0.05$ , \*\*\*\*  $p < 0.0001$ ).  $n = 4$  per condition, data represents an average across triplicate wells and multiple plates.

(C) siRNA-mediated knockdown of SIRT1 prevents the ability of CLOCK to repress transcriptional activity, while SIRT1 further represses activity when co-transfected with CLOCK (one-way ANOVA,  $F_{3,32} = 3503$ ,  $p < 0.0001$ ; Tukey's post hoc tests, \*  $p < 0.05$ , \*\*\*  $p < 0.001$ , \*\*\*\*  $p < 0.0001$ ).  $n = 4$  per condition, data represents an average across triplicate wells and multiple plates.

(D) SIRT1 restores the ability of CLOCK 19 to repress transcriptional activity (one-way ANOVA,  $F_{2,9} = 76.5$ ,  $p < 0.0001$ ; Tukey's post hoc tests, \*\*  $p < 0.01$ , \*\*\*  $p < 0.001$ ).  $n = 4$  per condition, data represents an average across triplicate wells and multiple plates.

(E) *TH:luc* activity was measured in Wt, SIRT1 KO, and CLOCK KO MEFs. SIRT1 is required for CLOCK to prevent CREB-induced transcriptional activity (genotype  $\times$  condition,  $F_{6,40} = 3503$ ,  $p < 0.0001$ ). CLOCK represses CREB-induced transcriptional activity in Wt (a TH vs. TH/CREB,  $p < 0.01$ ; b TH/CREB vs. TH/CREB/CLOCK,  $p < 0.0001$ ) and CLOCK KO (c TH/CREB vs. TH/CREB/CLOCK,  $p < 0.0001$ ) MEFs, but fails to do so in SIRT1 KO MEFs. Co-transfection of CLOCK and SIRT1 in CLOCK KO MEFs prevents CREB-induced transcriptional activity (d TH/CREB/CLOCK vs. TH/CREB/CLOCK/SIRT1  $p < 0.001$ ).  $n = 4-5$  per condition, data represents an average across triplicate wells and multiple plates.

(F) CLOCK KO MEFs were transfected with either partial domains or full SIRT1: 1) GEX vector backbone control; 2) N-terminus (required for CLOCK interaction<sup>24</sup>; or 3) catalytic domain. Full SIRT1 and partial N-terminus SIRT1 prevents CREB-induced *TH:luc* activity, with no effect of partial catalytic SIRT1 (one-way ANOVA,  $F_{4,20} = 68.14$ ,  $p < 0.0001$ ; Tukey's post hoc tests, \*\*\*  $p < 0.001$ ).  $n = 4-6$  per condition, data represents an average across triplicate wells and multiple plates. Transfected construct (+). All data are represented as mean  $\pm$  SEM.

(G) PC12 cells were treated with NAD<sup>+</sup> (1 $\mu$ M), harvested 72 hrs later then measured *TH:luc* activity. CLOCK and NAD<sup>+</sup> prevent CREB-induced *TH:luc* activity (one-way ANOVA,  $F_{8,27} = 16.23$ ,  $p < 0.0001$ ; Tukey's post hoc tests, \*\*  $p < 0.01$ , \*\*\*\*  $p < 0.0001$ ).  $n = 4$  per condition, data represents an average across triplicate wells and multiple plates.

(H) PC12 cells were treated with NAM (10mM), harvested 72 hrs later then measured *TH:luc* activity. NAM prevents CLOCK-mediated repression of *TH:luc* activity (one-way ANOVA,  $F_{8,27} = 16.23$ ,  $p < 0.0001$ ; Tukey's post hoc tests, \*\*\*\*  $p < 0.0001$ ).  $n = 4$  per condition, data represents an average across triplicate wells and multiple plates.

(I) PC12 cells were treated with varying concentrations of NAD<sup>+</sup>, harvested 48 hrs later then measured *TH:luc* activity. NAD<sup>+</sup> further reduces *TH:luc* activity regardless of dose relative to CLOCK (one-way ANOVA,  $F_{6,21} = 118.1$ ,  $p < 0.0001$ ; Tukey's post hoc tests, \*\*\*\*  $p < 0.0001$ , a TH vs. TH/CREB,  $p < 0.0001$ , b TH/CREB vs. TH/CREB/CLOCK,  $p < 0.05$ , c TH/CREB/CLOCK vs. TH/CREB/CLOCK + NAD<sup>+</sup>,  $p < 0.05$ ).  $n = 4$  per condition, data represents an average across triplicate wells and multiple plates.

(J) siRNA-mediated knockdown of SIRT1 leads to increased *TH:luc* activity in the presence of NAD<sup>+</sup> (one-way ANOVA,  $F_{5,18} = 67.56$ ,  $p < 0.0001$ ; Tukey's post hoc tests, a TH/CREB/CLOCK/SIRT1<sub>siRNA</sub> vs. TH/CREB/CLOCK/SIRT1<sub>siRNA</sub> + NAD<sup>+</sup> (100 $\mu$ M),  $p < 0.05$ , b TH/CREB/CLOCK/SIRT1<sub>siRNA</sub> vs. TH/CREB/CLOCK/SIRT1<sub>siRNA</sub> + NAD<sup>+</sup> (2000 $\mu$ M),  $p < 0.05$ .  $n = 4$  per condition, data represents an average across triplicate wells among multiple

plates. n=4 per condition, data represents an average across triplicate wells and multiple plates.

(K) PC12 cells were transfected, treated with NMN (200 $\mu$ M), then harvested after 72hrs to measure *TH:luc* activity. One-way ANOVA followed by Tukey's multiple comparisons tests, \*\*\*\* p<0.0001. <sup>a</sup> TH/CREB + NMN vs. TH/CREB/SIRT1 + NMN, p<0.0001. n=6 per

condition, data represents an average across triplicate wells among multiple plates. n=6 per

condition, data represents an average across triplicate wells and multiple plates.

(L) Transfected Wt and SIRT1 KO MEFs were treated with NMN (400 or 800 $\mu$ M), then harvested 48–72hrs later to *TH:luc* activity. The repressive effects of NMN on *TH:luc*


activity depended on SIRT1 and CLOCK (genotype  $\times$  condition,  $F_{4,30}=50.4$ , p<0.0001,

Tukey's post hoc tests, \*\* p<0.01, \*\*\*\* p<0.0001, a condition vs. TH/CREB Wt MEFs,

p<0.0001, b condition vs. TH/CREB SIRT1 KO MEFs, p<0.05. n=4 per condition, data

represents an average across triplicate wells and multiple plates.

Transfected construct (+). All data are represented as mean  $\pm$  SEM.



**Figure 3. CLOCK and SIRT1 Reduce TH Expression in Neural Cells and In Vivo**

(A) Mouse N2A cells transfected with *TH:Luc* and CLOCK has no effect on bioluminescence activity.

(B) CLOCK and SIRT1 block CREB-induced *TH:Luc* activity in mouse N2A cells (one-way ANOVA,  $F_{4,25}=279.7$ ,  $p<0.0001$ ; Tukey's post hoc tests, \*\*\*\*  $p<0.0001$ ).  $n=6$  per condition, data represents an average across triplicate wells and multiple plates.

(C) Separate cohorts of mice were injected with HSV-SIRT1 (or GFP, 2–3 days of expression) or AAV5-mCREB (or GFP, 3–4 weeks of expression) into the VTA. Triple-


labeling immunohistochemistry shows robust viral expression in the VTA (green, GFP; red, TH; and blue, DAPI).

(D) Resveratrol reduces *TH* expression in the VTA of Wt and *Clock*<sup>-19</sup> mice (genotype,  $F_{1,20}=25.67$ ,  $p<0.0001$ , treatment,  $F_{1,20}=42.09$ ,  $p<0.0001$ , and genotype  $\times$  treatment,  $F_{1,20}=4.8$ ,  $p=0.04$ ; Tukey's post hoc tests, \*  $p<0.05$ , \*\*\*\*  $p<0.0001$ , # VEH Wt vs. VEH *Clock*<sup>-19</sup>,  $p<0.01$ ).

(E) Overexpression of SIRT1 reduces *TH* expression in the VTA of Wt and *Clock*<sup>-19</sup> mice (genotype,  $F_{1,20}=29.44$ ,  $p<0.0001$ , treatment,  $F_{1,20}=213.4$ ,  $p<0.0001$ , and genotype  $\times$  treatment,  $F_{1,20}=40.88$ ,  $p<0.0001$ ; Tukey's post hoc tests, \*\*\*\*  $p<0.0001$ , # VEH Wt vs. VEH *Clock*<sup>-19</sup>,  $p<0.0001$ ).

(F) mCREB reduces *TH* expression only in *Clock*<sup>-19</sup> mice (genotype  $\times$  virus,  $F_{1,20}=37.05$ ,  $p<0.0001$ ; Tukey's post hoc tests, \*  $p<0.05$ , \*\*\*\*  $P<0.0001$ , # AAV5-GFP Wt vs. *Clock*<sup>-19</sup>,  $p=0.004$ ).





**Figure 4. Resveratrol Modulation of DA Cell Excitability and Striatal DA Levels Depends on a Functional CLOCK protein**

(A) Representative traces of action potentials during current injection of VTA DA neurons treated with DMSO or resveratrol from Wt and *Clock*<sup>Δ19</sup> mice. Whole-cell traces from DMSO treated slices are similar between genotypes (single trace pictured).

(B) Resting membrane potential of VTA DA neurons in *Clock*<sup>Δ19</sup> mice are depolarized, indicating enhanced intrinsic excitability (t=2.2, p<0.05). n=7 cells per genotype.

(C) Action potentials elicited by 200pA injection into VTA DA neurons during DMSO or resveratrol (RES) application. RES increases and decreases spike frequency in Wt mice (t=2.44, p<0.05) and *Clock*<sup>Δ19</sup> (t=9.34, p<0.001) mice, respectively.

(D) RES increases and decreases spike frequency in Wt (t=2.13, a p<0.05) and *Clock*<sup>Δ19</sup> (t=7.1, b p<0.001) mice relative to baseline.


(E) Minimum current required to elicit an action potential indicates RES selectively (Wt, p=0.11) enhances the rheobase ('excitability') of VTA DA neurons from *Clock*<sup>Δ19</sup> mice (t=4.40, p<0.01).

(F) RES enhances the rheobase relative to baseline of VTA DA neurons from *Clock*<sup>Δ19</sup> mice (t=3.81, p<0.01).

(G,H) Levels of DA, DOPAC and HVA were measured in the NAc and dSTR of Wt and *Clock*<sup>-/-</sup> mice at ZT8–10, when *TH* expression is approaching the peak in *Clock*<sup>-/-</sup> mice. Resveratrol increases DA in the NAc and dSTR of Wt mice and decreases DA in the NAc of *Clock*<sup>-/-</sup> mice ((G, left) NAc: genotype × treatment,  $F_{1,20}=14.34$ ,  $p<0.01$ ; Tukey's post hoc tests, a Saline Wt vs. *Clock*<sup>-/-</sup>  $p<0.001$ , \*  $p<0.05$ , \*\*\*  $p<0.001$ ; and (H, left) dSTR: genotype,  $F_{1,20}=5.96$ ,  $p<0.05$ ; Tukey's post hoc tests, a Saline Wt vs. *Clock*<sup>-/-</sup>  $p<0.05$ , \*  $p<0.05$ ). Resveratrol decreases DOPAC in NAc of *Clock*<sup>-/-</sup> mice ((G, middle), genotype × treatment,  $F_{1,20}=13.8$ ,  $p<0.01$ ; Tukey's post hoc tests, a Saline Wt vs. *Clock*<sup>-/-</sup> mice  $p<0.05$ , \*  $p<0.05$ ), with no overall effect on HVA ((G, right), genotype,  $F_{1,20}=20.1$ ,  $p<0.001$ ).

All data are represented as mean ± SEM.

(I) Schematic of diurnal regulation of *TH* by CLOCK/SIRT1 and CREB. During the day (inactive phase), CLOCK and SIRT1 bind to the proximal E-box within the *TH* promoter, when *TH* expression is low. Oscillating NAD<sup>+</sup> (and NAM) may modulate the activity of SIRT1 and repression of transcriptional activity. During the night (active phase), CREB is recruited to the CRE site to promote the transcriptional activity of *TH*. In *Clock*<sup>-/-</sup> mice, recruitment of SIRT1 to the promoter is reduced potentially due to reduced expression during the day, while P-CREB binding is enhanced during the day and night. Elevated P-CREB activity constitutively increases TH protein expression in *Clock*<sup>-/-</sup> mice. CLOCK promoter binding during the day may prevent CREB from binding the CRE site. The truncated mutant CLOCK protein (missing 51 amino acids of the transactivational domain) or the inability to recruit other cofactors to the transcriptional complex permits CREB binding. Thus, CLOCK could block CREB from accessing the CRE site, suggesting steric hindrance.



**Figure 5. *In vivo* Regulation of TH Expression and Cocaine Conditioned Place Preference (CPP) by SIRT1 and CREB Depends on a Functional CLOCK Protein**

(A) Mice were administered resveratrol (red syringes; 20mg/kg, i.p.) each conditioning day and saline (gray syringes) or cocaine (blue syringes; 5mg/kg, i.p.) on alternating conditioning days. Another cohort of mice was administered NMN (brown syringes; 500mg/kg, i.p.) at ZT9–11 on days 1–5. Separate cohorts of mice were injected with HSV-SIRT1 (or GFP, 2–3 days of expression) or AAV5-mCREB (or GFP, 3–4 weeks of expression) into the VTA prior to cocaine CPP. n=9 per group RESV CPP; n=10–11 per group SIRT1OX CPP; n=10 per group mCREB CPP; and n=9–10 per group NMN CPP.

(B–E) Resveratrol, NMN, HSV-SIRT1, and AAV5-mCREB increases and decreases *TH* expression in Wt and *Clock*<sup>19</sup> mice, respectively (resveratrol, genotype,  $F_{1,20}=4.78$ ,  $p=0.04$  and genotype  $\times$  treatment,  $F_{1,20}=44.74$ ,  $p<0.0001$ ; Tukey's post hoc tests, a Vehicle Wt vs. *Clock*<sup>19</sup>  $p<0.05$ , \*\*  $p<0.01$ , \*\*\*  $p<0.001$ ; NMN, genotype  $\times$  treatment,  $F_{1,20}=14.8$ ,  $p<0.001$ ; Tukey's post hoc tests, a Vehicle Wt vs. *Clock*<sup>19</sup>  $p<0.05$ , \*  $p<0.05$ ; HSV-SIRT1, genotype  $\times$  virus,  $F_{1,20}=25.75$ ,  $p<0.0001$ ; Tukey's post hoc tests, a HSV-GFP Wt vs. *Clock*<sup>19</sup>  $p<0.05$ , \*\*  $p<0.01$ ; and AAV5-mCREB, genotype,  $F_{1,20}=14.48$ ,  $p=0.001$ , virus,  $F_{1,20}=4.62$ ,  $p=0.04$ , and genotype  $\times$  virus,  $F_{1,20}=60.81$ ,  $p<0.0001$ ; Tukey's post hoc tests, a AAV5-GFP  $p<0.05$ , \*\*  $p<0.001$ , \*\*\*\*  $p<0.0001$ ).

(F–I) Resveratrol, NMN, HSV-SIRT1, and AAV5-GFP promotes and attenuates cocaine CPP in Wt and *Clock*<sup>19</sup> mice, respectively (resveratrol, genotype  $\times$  treatment,  $F_{1,32}=20.28$ ,  $p<0.0001$ , Tukey's post hoc tests, a Vehicle Wt and *Clock*<sup>19</sup>  $p<0.05$ , \*  $p<0.05$ , \*\*  $p<0.01$ ; NMN, genotype  $\times$  treatment,  $F_{1,34}=27.34$ ,  $p<0.0001$ , Tukey's post hoc tests, a Vehicle Wt vs. *Clock*<sup>19</sup>  $p<0.01$ , \*  $p<0.05$ , \*\*\*  $p<0.001$ ; HSV-SIRT1, genotype  $\times$  virus,  $F_{1,38}=16.86$ ,  $p=0.0002$ ; Tukey's post hoc tests, a HSV-GFP Wt and *Clock*<sup>19</sup>  $p<0.05$ , \*  $p<0.05$ ; and AAV5-mCREB, genotype  $\times$  virus,  $F_{1,36}=10.4$ ,  $p=0.003$ ; Tukey's post hoc tests, a AAV5-GFP Wt vs. *Clock*<sup>19</sup>,  $p<0.01$ , \*  $p<0.05$ ).